Clover Corporation Limited · ASX:CLV
Clover — Shareholder Meeting (November 2025)
39 slides from Clover's shareholder meeting presentation, Nov 18, 2025
Slide 1: FY25 Annual General Meeting
FY25 Annual General Meeting November 2025 Chair Rupert Harrington CEO Peter Davey
Slide 2: Welcome
Clover Corporation Limited Welcome FY25 Annual General Meeting 2
Slide 3: Board members
Board members Rupert Harrington Peter Davey Toni Brendish Chair Managing Director & CEO Non-Executive Director Graeme Billings Dr. Simon Green Ian Glasson Fiona Pearse Non-Executive Director Non-Executive Director Non-Executive Director Non-Executive Director 3
Slide 4: Agenda
Agenda Formal business 02 Welcome 24 Item 1 – Adoption of annual accounts 03 Introductions 25 Item 2 – Retirement of Graeme Billings 05 How to ask questions 26 Item 3 – Resolution 1: Adoption of remuneration report 06 How to vote 28 Item 4 – Resolution 2: Re-election of Dr Simon Green 07 Chairman’s
Slide 5: How to ask a questions
How to ask a questions • To ask a written question select the Q&A icon • Select the topic your question relates to from the drop-down list • Type your question in the text box and press the send button • To ask a verbal question follow the instructions below the broadcast window. 5
Slide 6: How to vote
How to vote • When the poll is open, select the vote icon at the top of the screen • To vote, select either For, Against or Abstain • You will see a vote confirmation • To change or cancel your vote, “click here to change your vote” at any time until the poll is closed 6
Slide 7: Chairman’s Address
Chairman’s Address
Slide 8: Managing Director’s Presentation on FY25 Results
Managing Director’s Presentation on FY25 Results 8
Slide 9: Full year financial highlights
Full year financial highlights Revenue Up 38% on pcp, driven by Human Nutrition growth and new products. $86m EBITDA Up 217% on pcp. $12.2m NPAT $7.1m $8.9m Cash Up 370% on pcp reflecting stronger Strong balance sheet strengthened margins and operational discipline. through debt repayment Operating
Slide 10: FY25 Operational highlights
FY25 Operational highlights • Record revenue, with new customers significantly increasing order numbers. • Existing infant formula customers expanded into adult, senior, and children’s nutrition segments. • Appointment of distributors across North America, Asia and Europe improving access to markets
Slide 11: Full year 2025 Profit and Loss
Full year 2025 Profit and Loss • FY25 delivered strong revenue growth, Reported Reported underpinned by expansion in Europe & Asia across Movement AUD Million 31 Jul 2025 31 Jul 2024 nutraceutical, food & beverage, and infant formula (A$M) (A$M (A$M) sectors. • NPAT increased significantly, driven b
Slide 12: Balance Sheet
Balance Sheet Reported Reported Movement 31 Jul 2025 31 Jul 2024 (A$M) (A$M) (A$M) Cash 8.7 12.3 -3.6 • Balance sheet strengthened, with net assets up YoY, supported by increases in working capital Trade receivables 25.1 13.7 +11.4 and reduced borrowings. Inventories 24.1 29.6 -5.5 • Cash position r
Slide 13: New products driving growth
New products driving growth 13
Slide 14: CholineXcel
CholineXcel • CholineXcel is a unique, flowable • Clover has applied for a global powder designed to improve patent for CholineXcel handling and stability in technology. manufacturing. • CholineXcel presented at Supply • Clover completed commercial- Side Global major food scale production trials in
Slide 15: Premneo Adult & Infant Formula
Premneo Adult & Infant Formula Global infant formula market appears to have stabilised. Growth driven by diversifying into non-allergenic formulations and enhanced fortification. Online sales in China increasing. DHA applications are expanding, with new growth opportunities in nutraceuticals, sports
Slide 16: Other products
Other products Highly concentrated oils Gelphorm Probiotics Sales of powdered High Omega 3 Unique double emulsion DHA Probiotics are live organisms which in nutraceuticals, petfood and product that can pass through UHT quickly die when unfrozen. Food for Special Medical Purposes process with no sens
Slide 17: Strategy and outlook
Strategy and outlook 17
Slide 18: The opportunity in China
The opportunity in China China represents a growth China remains the largest global consumer opportunity by FY29. market for DHA and nutritional ingredients. • Structural recovery in human nutrition; strong growth in toddler, senior, & adult nutrition. • Expanding online and cross-border e- commerce
Slide 19: Strategy for growth
Strategy for growth Accelerate commercialisation of new products Expand market reach Diversify into adjacent high-growth markets Deepen customer value and retention 19
Slide 20: FY26 Trading Update
FY26 Trading Update 1 We are seeing continued momentum and growth with core human nutrition customers. We are continuing to appoint new distributors to broaden sales reach and diversify Clover’s customer base across 2 segments and geographies. 3 Ecuador facility is currently supplying 30% of the tar
Slide 21: FY26 Outlook
FY26 Outlook Based on current sales and forecasted demand, the Board now expects 1H FY26 revenue to be in a range of $40m - $43m. Assuming demand momentum continues and supply chain remains stable, we expect that the full year revenue should outperform FY25. Clover Corp | Investor Presentation Septe
Slide 22: Disclaimer
Disclaimer The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe such restrictions. This
Slide 23: Formal Business
Formal Business 23
Slide 24: Adoption of annual accounts
01 Adoption of annual accounts 24
Slide 25: Retirement of Graeme Billings
02 Retirement of Graeme Billings 25
Slide 26: Resolution 1: Adoption of remuneration report
03 Resolution 1: Adoption of remuneration report 26
Slide 27: Resolution 1 Remuneration Report Proxy Votes
For Voted 73,625,100 % 96.75 Resolution 1 Against 968,453 1.27 Open-Usable Abstain 1,508,755 52,275 1.98 N/A Remuneration Report Excluded 545,333 N/A 100.0 Proxy Votes 27
Slide 28: Resolution 2: Re-election of Dr Simon Green
04 Resolution 2: Re-election of Dr Simon Green 28
Slide 29: Resolution 2 Re-elect Dr Simon Green Proxy Votes
Resolution 2 Voted % For 74,278,539 96.96 Re-elect Dr Simon Green Against Open-Usable 823,513 1,509,855 1.07 1.97 Abstain 31,775 N/A Proxy Votes Excluded 56,234 N/A 100.0 29
Slide 30: Resolution 3: Election of Fiona Pearse
05 Resolution 3: Election of Fiona Pearse 30
Slide 31: Resolution 3 Elect Ms Fiona Pearse Proxy Votes
Voted % Resolution 3 For 74,168,231 96.93 Against 841,027 1.10 Open-Usable 1,509,855 1.97 Elect Ms Fiona Pearse Abstain 31,775 N/A Proxy Votes Excluded 149,028 N/A 100.0 31
Slide 32: Resolution 4: Approve acquisition of performance rights by the Managing Director
06 Resolution 4: Approve acquisition of performance rights by the Managing Director 32
Slide 33: Resolution 4 Performance Rights MD Proxy Votes
Resolution 4 For Voted 72,474,808 % 94.71 Against 2,544,372 3.32 Performance Rights MD Open-Usable 1,513,459 1.97 Abstain 167,277 N/A Excluded - N/A Proxy Votes 100.0 33
Slide 34: Resolution 5: Approval of long-term incentive plan
07 Resolution 5: Approval of long-term incentive plan 34
Slide 35: Resolution 5 Long Term Incentive Plan Proxy Votes
Voted % Resolution 5 For 73,675,902 96.63 Against Open-Usable 1,059,111 1,509,555 1.39 1.98 Long Term Incentive Plan Abstain 175,277 N/A Excluded 280,071 N/A 100.0 Proxy Votes 35
Slide 36: Resolution 6: Adoption of a new constitution
08 Resolution 6: Adoption of a new constitution 36
Slide 37: Resolution 6 Adopt New Constitution Proxy Votes
Resolution 6 Voted % For 74,439,959 95.89 Against 1,634,620 2.13 Adopt New Constitution Open-Usable 1,519,855 1.98 Abstain 105,482 N/A Excluded - N/A Proxy Votes 100.0 37
Slide 38: Voting poll & close
“ = | , — Voting poll & close
Slide 39: Questions
Questions 39